Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CCCC 
C4 Therapeutics Inc (CCCC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CCCC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $14.5
1 Year Target Price $14.5
| 4 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.5% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 189.31M USD | Price to earnings Ratio - | 1Y Target Price 14.5 |
Price to earnings Ratio - | 1Y Target Price 14.5 | ||
Volume (30-day avg) 8 | Beta 3 | 52 Weeks Range 1.08 - 7.14 | Updated Date 09/15/2025 |
52 Weeks Range 1.08 - 7.14 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -440.99% |
Management Effectiveness
Return on Assets (TTM) -22.8% | Return on Equity (TTM) -52.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37683367 | Price to Sales(TTM) 5.53 |
Enterprise Value 37683367 | Price to Sales(TTM) 5.53 | ||
Enterprise Value to Revenue 1.1 | Enterprise Value to EBITDA -0.42 | Shares Outstanding 71170800 | Shares Floating 50029524 |
Shares Outstanding 71170800 | Shares Floating 50029524 | ||
Percent Insiders 9.75 | Percent Institutions 76.95 |
Upturn AI SWOT
C4 Therapeutics Inc
Company Overview
History and Background
C4 Therapeutics (founded in 2011) is a biopharmaceutical company focused on developing targeted protein degradation therapeutics. They aim to develop new treatments for cancer, neurodegenerative conditions and other diseases by selectively degrading disease-causing proteins.
Core Business Areas
- Targeted Protein Degradation Platform: C4T's core technology is a proprietary platform designed to leverage the ubiquitin-proteasome system to selectively degrade disease-causing proteins. This platform drives their drug discovery and development efforts.
- Drug Development Programs: Focus on oncology indications with programs targeting specific cancer-driving proteins. The company develops small-molecule drugs that induce the degradation of target proteins.
Leadership and Structure
Andrew Hirsch serves as President and Chief Executive Officer. The company's organizational structure is composed of research & development, clinical development, and corporate functions.
Top Products and Market Share
Key Offerings
- CFT7455: An oral MonoDAC degrader of IKZF1/3, for the treatment of multiple myeloma (MM) and peripheral T-cell lymphomas (PTCL). Currently in clinical trials. Competitors include companies developing other treatments for MM and PTCL such as Bristol Myers Squibb (BMY) and Takeda (TAK).
- CFT1946: A BRAF V600E degrader designed to be highly potent and selective for BRAF V600E monomer degradation with encouraging early clinical data in BRAF V600E-mutant melanoma. Currently in clinical trials. Competitors include companies developing BRAF inhibitors, such as Roche (RHHBY) and Novartis (NVS).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, characterized by long development timelines and significant regulatory hurdles. Targeted protein degradation is an emerging field with significant potential to treat diseases by targeting previously undruggable proteins.
Positioning
C4 Therapeutics is positioned as a leader in the targeted protein degradation field, with a proprietary technology platform and a pipeline of promising drug candidates. They compete with other companies developing similar technologies and traditional drug development companies.
Total Addressable Market (TAM)
The total addressable market for targeted protein degradation therapies is potentially very large, given the broad range of diseases that can be addressed using this approach. Estimates vary widely, but potentially exceeds $100 billion across oncology, neurodegeneration, and other disease areas. C4 Therapeutics is focused on capturing a portion of this market through its drug development programs.
Upturn SWOT Analysis
Strengths
- Proprietary targeted protein degradation platform
- Strong intellectual property portfolio
- Experienced management team
- Pipeline of promising drug candidates
- Strategic partnerships with pharmaceutical companies
Weaknesses
- Clinical trial risk
- High cash burn rate
- Dependence on successful development of pipeline drugs
- Relatively small size compared to larger pharmaceutical companies
Opportunities
- Expanding the pipeline of drug candidates
- Entering new therapeutic areas
- Forming new strategic partnerships
- Advancing drugs through clinical trials
- Targeting previously undruggable proteins
Threats
- Competition from other biopharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- KYMR
- ARVN
- MDGL
- VRTX
Competitive Landscape
C4 Therapeutics holds a competitive advantage with its novel targeted protein degradation platform, however faces challenges related to funding and clinical development against larger, more established companies.
Growth Trajectory and Initiatives
Historical Growth: As a development-stage company, historical growth is primarily reflected in pipeline advancement and partnerships. Key growth indicators include progress in clinical trials and expansion of its research platform.
Future Projections: Future growth depends on clinical trial success and potential regulatory approvals. Analyst estimates vary but generally project revenue growth contingent on successful commercialization of drug candidates.
Recent Initiatives: Recent initiatives include advancing CFT7455 and CFT1946 through clinical trials, expanding collaborations with pharmaceutical partners, and continuing investment in its targeted protein degradation platform.
Summary
C4 Therapeutics is a biopharmaceutical company pioneering targeted protein degradation, with promising clinical-stage drug candidates. It faces inherent risks of the drug development process and competition from larger pharmaceutical firms. Successful clinical trials and strategic partnerships will be critical for its future growth. It should carefully monitor its cash burn rate and maintain a strong intellectual property position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share data is an estimate and may not reflect precise values.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About C4 Therapeutics Inc
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2020-10-02 | CEO, President & Director Mr. Andrew J. Hirsch M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 110 | Website https://www.c4therapeutics.com |
Full time employees 110 | Website https://www.c4therapeutics.com | ||
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.